目的 探讨左西孟旦在治疗急性广泛前壁心肌梗死心力衰竭患者中的疗效.方法 选取2019年10月～2021年10月本院收治的90例急性前壁心肌梗死合并心力衰竭患者为研究对象,并依据随机数表法将其分成两组,对照组(45例),实验组(45例),对照组采用多巴酚丁胺治疗,实验组采用左西孟旦药物治疗,对比两组患者治疗前后测定血浆B型脑钠肽前体(Pro-BNP)、左室射血分数(LVEF)、临床疗效、不良反应.结果 治疗前,两组患者的Pro-BNP和LVEF相比无显著差异(P＞0.05),治疗后,实验组患者和对照组患者的“,”Objective To investigate the efficacy of levsimendan in the treatment of patients with acute extensive anterior wall myocardial infarction. Methods 90 patients with acute anterior wall myocardial infarction and heart failure from October 2019 to October 2021, were selected and divided into two groups, control (45 cases), dobutamine, levsimendan and plasma B (Pro-BNP), LV ejection fraction (LVEF), clinical efficacy and adverse effects. Results Before the treatment, There was no significant difference between Pro-BNP and LVEF between the two groups (P＞ 0.05), post-treatment, The Pro-BNP and LVEF were improved significantly in both the experimental and control patients (P＜0.05), The comparative difference between Pro-BNP and LVEF between patients before and 72h after treatment was statistically significant (P＜0.05); The total incidence of adverse effects of arrhythmia, hypotension, palpitations, headache, vertigo, and nausea accounted for 13.3％, The incidence of adverse reactions with dobutamine was 55.6％, Comparing the two sets of results, The adverse reactions in the experimental group were significantly lower than in the control group (P＜0.05); The total clinical efficiency of the experimental group was 93.3％, The overall clinical effective rate of controls treated with dobutamine was 73.3％, Comparing the two sets of results, The total efficiency of the experimental group was significantly higher than that in the control group, (P＜0.05).Conclusion Patients with acute PMI can reduce the adverse effects after treatment, but not for 6 months of compound clinical key events, but the tolerance of the drug is high to the patients.